Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ibrolipim (NO-1886) 是口服具有活力的脂蛋白脂肪酶 (LPL) 激活剂。它能够降低血浆甘油三酸酯,增加高密度脂蛋白胆固醇水平,具有肾保护和降血脂的作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 153 | 现货 | ||
5 mg | ¥ 328 | 现货 | ||
10 mg | ¥ 538 | 现货 | ||
25 mg | ¥ 955 | 现货 | ||
50 mg | ¥ 1,450 | 现货 | ||
100 mg | ¥ 2,180 | 现货 | ||
200 mg | ¥ 3,280 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 363 | 现货 |
产品描述 | Ibrolipim (NO-1886) attenuates high glucose-induced endothelial dysfunction in cultured human umbilical vein endothelial cells via PI3K/Akt pathway. |
体外活性 | Ibrolipim?5 and 50 μmol/L significantly increased cholesterol efflux from THP-1 macrophage-derived foam cells to apoA-I or HDL. Moreover, it upregulated the expression of ABCA1 and ABCG1. In addition, LXRα was also upregulated by the?ibrolipim?treatment. In addition, LXRα small interfering RNA completely abolished the promotion effect that was induced by?ibrolipim[1]. |
体内活性 | Ibrolipim (NO-1886; 100 mg/kg; oral administration; daily; for 8 weeks; female Sprague-Dawley rats) treatment decreases accumulation of visceral fat and suppresses the increase in body weight resulting from the ovariectomy. Ibrolipim decreases the respiratory quotient and increases expression of the fatty acid translocase messenger RNA (mRNA) in the liver, soleus muscle, and mesenteric fat. Ibrolipim also increases the expression of fatty acid-binding protein mRNA in the liver and soleus muscle and the expression of the uncoupling protein 3 (UCP3) mRNA in the heart, soleus muscle, and mesenteric fat, but not in the brown adipose tissue[2] |
细胞实验 | Human THP-1 cells pre-incubated with ox-LDL served as foam cell models. Specific mRNA was quantified using real-time RT-PCR and protein expression using Western blotting. Cellular cholesterol handling was studied using cholesterol efflux experiments and high performance liquid chromatography assays[1] |
动物实验 | Animal Model: Female Sprague-Dawley rats (10-week-old; 200-260 g) with experimental ovariectomy treatment. Dosage: 100 mg/kg ? ? ??. Administration: Oral administration; daily; for 8 weeks[2] |
别名 | NO-1886 |
分子量 | 451.25 |
分子式 | C19H20BrN2O4P |
CAS No. | 133208-93-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (277.01 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.2161 mL | 11.0803 mL | 22.1607 mL | 55.4017 mL |
5 mM | 0.4432 mL | 2.2161 mL | 4.4321 mL | 11.0803 mL | |
10 mM | 0.2216 mL | 1.108 mL | 2.2161 mL | 5.5402 mL | |
20 mM | 0.1108 mL | 0.554 mL | 1.108 mL | 2.7701 mL | |
50 mM | 0.0443 mL | 0.2216 mL | 0.4432 mL | 1.108 mL | |
100 mM | 0.0222 mL | 0.1108 mL | 0.2216 mL | 0.554 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ibrolipim 133208-93-2 GPCR/G Protein LPL Receptor obesity fatty inhibit acid Inhibitor lipoprotein lipase Antihyperlipidemic NO 1886 UCP3 NO1886 LDL-C LXRα HDL-C NO-1886 inhibitor